ADMA Biologics, Inc. (NASDAQ:ADMA) is listed as one of the Stocks That Could Mint Millionaires in 2026. The company markets BIVIGAM and Nabi-HB products, with updated 2025 revenue guidance of $510 million and adjusted net income of $158 million due to a higher tax rate.

ADMA Biologics, Inc. (NASDAQ:ADMA) develops specialty plasma-derived biologics for immune deficiencies and infectious diseases. Despite its potential, some believe other AI stocks offer greater upside potential and less downside risk. A free report on the best short-term AI stock is available for those interested in investing.

For more financial insights, readers can explore articles on 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term. Disclosure: None.

Read more at Yahoo Finance: Firm Updates 2025 Revenue Guidance